{"id":960732,"date":"2026-05-11T08:56:40","date_gmt":"2026-05-11T12:56:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-announces-activation-of-childrens-hospital-of-philadelphia-as-a-new-qualified-treatment-center-for-zevaskyn\/"},"modified":"2026-05-11T08:56:40","modified_gmt":"2026-05-11T12:56:40","slug":"abeona-therapeutics-announces-activation-of-childrens-hospital-of-philadelphia-as-a-new-qualified-treatment-center-for-zevaskyn","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-announces-activation-of-childrens-hospital-of-philadelphia-as-a-new-qualified-treatment-center-for-zevaskyn\/","title":{"rendered":"Abeona Therapeutics\u00ae Announces Activation of Children’s Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN\u00ae"},"content":{"rendered":"
\n

CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced activation of the Children\u2019s Hospital of Philadelphia (CHOP) as the sixth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets.<\/p>\n

\u201cActivation of CHOP is a significant step forward for the Recessive dystrophic epidermolysis bullosa (RDEB) community expanding access to ZEVASKYN in the east coast,\u201d said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona. \u201cWe are excited to collaborate with Dr. Marissa J. Perman and her team, global leaders in pediatric care and pioneers in gene and cell therapy innovation, to enable more patients an opportunity to receive ZEVASKYN treatment.\u201d<\/p>\n

\u201cCHOP is proud to be named a treatment center for ZEVASKYN,\u201d said Marissa J. Perman, MD, Section Chief of Dermatology and Director of the Epidermolysis Bullosa Multidisciplinary Clinic at Children’s Hospital of Philadelphia. \u201cThis designation underscores our dedication to delivering leading-edge care and expanding access to promising new therapies that have the potential to enhance quality of life for patients with RDEB and their families.\u201d<\/p>\n

For more information about receiving ZEVASKYN treatment at CHOP, contact the Epidermolysis Bullosa Multidisciplinary Clinic<\/a> at EBclinic@chop.edu<\/a> or call 215-590-1930.<\/p>\n

For more information on how to access ZEVASKYN and learn about patient support services offered through Abeona Assist\u00ae<\/sup>, Abeona\u2019s comprehensive patient support program, visit\u00a0www.abeonaassist.com<\/a>, call 1-855-ABEONA-1 (1-855-223-6621) or email\u00a0MyNavigator@AbeonaAssist.com<\/a>. Abeona Assist offers personalized support, including helping eligible patients understand their insurance benefits and financial assistance options, and providing travel and logistical assistance.<\/p>\n

Marissa J. Perman, MD, has been a paid consultant to Abeona Therapeutics.<\/p>\n

\n About recessive dystrophic epidermolysis bullosa<\/strong>
\n
Recessive dystrophic epidermolysis bullosa (RDEB), a rare blistering disorder without a cure, is characterized by severe skin wounds that cause pain and can lead to systemic complications impacting the length and quality of life. People with RDEB have a defect in both copies of the COL7A1 gene, leaving them unable to produce functioning type VII collagen, which is necessary to anchor the dermal and epidermal layers of the skin.<\/p>\n

\n About ZEVASKYN<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n \u00a0(prademagene zamikeracel) gene-modified cellular sheets<\/strong>
\n
ZEVASKYN is the first and only autologous cell sheet-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a severe skin disease caused by a defect in both copies of the COL7A1 gene resulting in the inability to produce functional type VII collagen. Without functional type VII collagen and anchoring fibrils, the skin is fragile and blisters easily, leading to wounds that continually open and close, or fail to heal altogether. Patients often have large open wounds that can lead to serious life-threatening complications. ZEVASKYN incorporates the functional type VII collagen-producing COL7A1 gene into a patient\u2019s own skin cells, ex vivo, using a replication-incompetent retroviral vector to produce functional type VII collagen in treated wounds. ZEVASKYN has demonstrated clinically meaningful wound healing and pain reduction with a single surgical application. For more information, visit\u00a0www.ZEVASKYN.com<\/a>.<\/p>\n

\n Indication<\/strong>
\n
ZEVASKYN\u00ae<\/sup>\u00a0(prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).<\/p>\n

\n Important Safety Information<\/strong>\n <\/p>\n